Since 2016, Roche has been partnering with the New Zealand Society for Oncology (NZSO) to award the Roche Translational Cancer Research Fellowship. In 2024 we were pleased to increase the value of the award to $40,000
Translational research bridges the gap from basic science in the lab to clinical practice, in order to enhance human health and well-being. It’s sometimes referred to as bench to bedside to community. Research is most effective when clinicians and scientists work together and a key role of NZSO is to encourage collaboration between clinicians and scientists. Creating an opportunity for our community to collaborate to bring the greatest benefit to New Zealanders impacted by cancer.
The Roche award is unique and tailored to NZ researchers and cancer specialists. It gives opportunities to connect, collaborate and drive forward research that benefits patients with cancer. It has enabled key cancer researchers in NZ, since 2016, to bring ideas to life.
Could you be the next recipient? Get inspired!
Check out
Southern District, Te Whatu Ora - Health New Zealand; Department of Pathology, University of Otago
Dr Jim Smith and his multidisciplinary team of New Zealand experts in epigenomics have won the 2024 Roche Translational Cancer Research Fellowship (RTCRF).
The aim of their research project is to develop a targeted ctDNA-based DNA methylation panel for implementation alongside PSA, MRI, and other risk stratification data in a structured screening approach for men at risk of prostate cancer.
Dr Smith believes this innovative research programme will contribute to early prostate cancer detection, leading to improved survival, fewer unnecessary procedures, decreased cost of care, and a more equitable screening approach for NZ men.
Read more about Dr Jim Smith’s and Associate Professor Aniruddha Chatterjee’s work